TMS Co (TSE:4891) ROE % Adjusted to Book Value: 0.00% (As of Dec. 2025)


TSE:4891 TMS Co Ltd TSE:4891
31 GF Score
Price 円103.00
! 1 Warning Sign
View Full Analysis

What is TMS Co ROE % Adjusted to Book Value?

TMS Co TSE:4891 -0.96% 31 ROE % Adjusted to Book Value is 0.00% as of Dec. 2025. GuruFocus rates TSE:4891 with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

TMS Co's ROE % for the quarter that ended in Dec. 2025 was 0.00%. TMS Co's PB Ratio for the quarter that ended in Dec. 2025 was 2.12. TMS Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was 0.00%.

TMS Co ROE % Adjusted to Book Value Related Terms

TMS Co ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for TMS Co's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TMS Co ROE % Adjusted to Book Value Chart

TMS Co Annual Data
Trend Feb21 Feb22 Feb23 Feb24 Feb25
ROE % Adjusted to Book Value
0.00 0.00 -4.57 -7.07 -7.16

TMS Co Quarterly Data
Feb21 Feb22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Feb25 May25 Aug25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.00 0.00 -16.79 -10.93 0.00

TSE:4891 vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, TMS Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TMS Co ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TMS Co's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where TMS Co's ROE % Adjusted to Book Value falls into.


TSE:4891
31GF Score
TMS Co Ltd TSE:4891
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TMS Co ROE % Adjusted to Book Value Calculation

TMS Co's ROE % Adjusted to Book Value for the fiscal year that ended in Feb. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-21.06% / 2.94
=-7.16%

TMS Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / 2.12
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
TMS Co (TSE:4891) has a ROE % Adjusted to Book Value of 0.00% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on TMS Co and its competitors.
Is TMS Co's ROE % Adjusted to Book Value too high?
TMS Co's current ROE % Adjusted to Book Value is 0.00%. Overall, TMS Co has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does TMS Co's ROE % Adjusted to Book Value compare to VRTX and REGN?
TMS Co's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on TMS Co and its competitors. TMS Co's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TMS Co stock overvalued right now?
TMS Co (TSE:4891) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. TMS Co's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For TMS Co (TSE:4891), the current ROE % Adjusted to Book Value is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TMS Co Business Description

Address 1-9-11F, Fuchu-cho, Fuchu-shi, Tokyo, JPN, 183-0055
TMS Co Ltd is focused on researching, developing, manufacturing, and selling pharmaceuticals. The company is involved in conducting research and development of SMTP compounds, which are drug candidate substances targeting soluble epoxide hydrolase (sEH), an enzyme found in the human body. It is developing sEH inhibitors for various inflammatory diseases. The company's clinical pipeline comprises three compounds: TMS-007 (being developed as a potential treatment for acute cerebral infarction), which is in the late clinical stage, TMS-010, and JX09 (for resistant and poorly controlled hypertension) and TMS-008 (to target acute inflammatory diseases such as kidney injury and cancer cachexia), which are in the early clinical stage. In addition, it has TMS-009 as a backup compound for TMS-008.
31GF Score

Get the complete analysis for TSE:4891

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円103.00
Price